FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100687825> ?p ?o ?g. }

• W3100687825 endingPage "5" @default.
• W3100687825 startingPage "1" @default.
• W3100687825 abstract "Aim: This study aimed to describe clinical characteristics and real-life management of patients undergoing cardiac rhythm procedures and therapies while receiving apixaban. Methods: This observational, multicentre study prospectively collected data from patients with non valvular atrial fibrillation (AF) undergoing cardiac rhythm procedures (ablation, pacemaker/ cardioverter defibrillator (ICD) implantation, cardioversion) while receiving apixaban. Patients were followed for up to 30 (±5) days post-procedure. Complications occurring within the 30 days after the procedure were collected. Results: A total of 959 patients were enrolled at 25 centres (September 2015–September 2017). Of these, 115 (12.0%) patients underwent a pacemaker or ICD implantation, 359 (37.4%) AF ablation, 265 (27.6%) flutter ablation and 220 (22.9%) electrical cardioversion. Management of apixaban in the per procedural period was left to investigators’ preference. Early complications included 18 bleeding events (1 tamponade requiring drainage, 2 pericardial effusions without drainage, 11 non-major bleedings for catheter ablation, 4 for pacemaker/ICD implantation). The number of patients bridging from apixaban to heparin/low-molecular-weight heparin (LMWH) was higher for ablation than for the other procedures (51.2% for ablation vs 11.5% and 2.6% for patients undergoing pacemaker/ICD implantation and cardioversion, respectively; P<0.001); the median duration of bridging for all procedures was 24 hours. Comparing patients with and without bleeding events revealed a higher rate of heparin/LMWH bridging in patients with bleeding events (60% vs 35.9%; P=0.03). Conclusion: Periprocedural bridge from Apixaban to Heparin/LMWH during cardiac rhythm procedures is associated with an increased rate of bleeding events at 30 days. Among 959 patients with nonvalvular atrial fibrillation undergoing cardiac rhythm procedures while receiving apixaban, bridging to heparin/low-molecular-weight heparin was more common with ablation than with pacemaker/ICD implantation or cardioversion (51.2% vs 11.5% and 2.6%, respectively; P<0.001), and was associated with a risk of bleeding events (P=0.03). This observational, multicentre study provides important real-life data regarding the management of anticoagulation therapy in patients with nonvalvular atrial fibrillation undergoing cardiac rhythm procedures while receiving apixaban. • Among 959 patients treated at 25 French centres from September 2015 to September 2017 and followed for up to 30 (±5) days post-procedure, bridging to heparin/low-molecular-weight heparin was more common with ablation than with pacemaker/ICD implantation or cardioversion (51.2% vs 11.5% and 2.6%, respectively; P<0.001). • The median duration of bridging was 24 hours for all procedures, and switching was associated with an increased risk of bleeding events (P=0.03)." @default.
• W3100687825 created "2020-11-23" @default.
• W3100687825 creator A5006238785 @default.
• W3100687825 creator A5006429666 @default.
• W3100687825 creator A5020718588 @default.
• W3100687825 creator A5024466963 @default.
• W3100687825 creator A5045533178 @default.
• W3100687825 creator A5049303135 @default.
• W3100687825 creator A5051744539 @default.
• W3100687825 creator A5055131810 @default.
• W3100687825 creator A5073259085 @default.
• W3100687825 creator A5085096454 @default.
• W3100687825 date "2020-01-01" @default.
• W3100687825 modified "2023-10-15" @default.
• W3100687825 title "Switch To Heparin and Risk of Bleeding In Patients on Apixaban Undergoing Cardiac Rhythm Procedures: The Amper Af Study" @default.
• W3100687825 hasPublicationYear "2020" @default.
• W3100687825 type Work @default.
• W3100687825 sameAs 3100687825 @default.
• W3100687825 citedByCount "0" @default.
• W3100687825 crossrefType "journal-article" @default.
• W3100687825 hasAuthorship W3100687825A5006238785 @default.
• W3100687825 hasAuthorship W3100687825A5006429666 @default.
• W3100687825 hasAuthorship W3100687825A5020718588 @default.
• W3100687825 hasAuthorship W3100687825A5024466963 @default.
• W3100687825 hasAuthorship W3100687825A5045533178 @default.
• W3100687825 hasAuthorship W3100687825A5049303135 @default.
• W3100687825 hasAuthorship W3100687825A5051744539 @default.
• W3100687825 hasAuthorship W3100687825A5055131810 @default.
• W3100687825 hasAuthorship W3100687825A5073259085 @default.
• W3100687825 hasAuthorship W3100687825A5085096454 @default.
• W3100687825 hasConcept C126322002 @default.
• W3100687825 hasConcept C141071460 @default.
• W3100687825 hasConcept C164705383 @default.
• W3100687825 hasConcept C2775914520 @default.
• W3100687825 hasConcept C2776131983 @default.
• W3100687825 hasConcept C2776301958 @default.
• W3100687825 hasConcept C2777289489 @default.
• W3100687825 hasConcept C2777557582 @default.
• W3100687825 hasConcept C2777987278 @default.
• W3100687825 hasConcept C2778292772 @default.
• W3100687825 hasConcept C2778607678 @default.
• W3100687825 hasConcept C2778661090 @default.
• W3100687825 hasConcept C2779161974 @default.
• W3100687825 hasConcept C2780638905 @default.
• W3100687825 hasConcept C42219234 @default.
• W3100687825 hasConcept C71924100 @default.
• W3100687825 hasConceptScore W3100687825C126322002 @default.
• W3100687825 hasConceptScore W3100687825C141071460 @default.
• W3100687825 hasConceptScore W3100687825C164705383 @default.
• W3100687825 hasConceptScore W3100687825C2775914520 @default.
• W3100687825 hasConceptScore W3100687825C2776131983 @default.
• W3100687825 hasConceptScore W3100687825C2776301958 @default.
• W3100687825 hasConceptScore W3100687825C2777289489 @default.
• W3100687825 hasConceptScore W3100687825C2777557582 @default.
• W3100687825 hasConceptScore W3100687825C2777987278 @default.
• W3100687825 hasConceptScore W3100687825C2778292772 @default.
• W3100687825 hasConceptScore W3100687825C2778607678 @default.
• W3100687825 hasConceptScore W3100687825C2778661090 @default.
• W3100687825 hasConceptScore W3100687825C2779161974 @default.
• W3100687825 hasConceptScore W3100687825C2780638905 @default.
• W3100687825 hasConceptScore W3100687825C42219234 @default.
• W3100687825 hasConceptScore W3100687825C71924100 @default.
• W3100687825 hasIssue "4" @default.
• W3100687825 hasLocation W31006878251 @default.
• W3100687825 hasOpenAccess W3100687825 @default.
• W3100687825 hasPrimaryLocation W31006878251 @default.
• W3100687825 hasRelatedWork W1985947292 @default.
• W3100687825 hasRelatedWork W1986869455 @default.
• W3100687825 hasRelatedWork W2015055148 @default.
• W3100687825 hasRelatedWork W2031570748 @default.
• W3100687825 hasRelatedWork W2099755014 @default.
• W3100687825 hasRelatedWork W2121718955 @default.
• W3100687825 hasRelatedWork W2363737649 @default.
• W3100687825 hasRelatedWork W2413329134 @default.
• W3100687825 hasRelatedWork W2728817124 @default.
• W3100687825 hasRelatedWork W2905121710 @default.
• W3100687825 hasRelatedWork W2920804236 @default.
• W3100687825 hasRelatedWork W2944931277 @default.
• W3100687825 hasRelatedWork W2945487909 @default.
• W3100687825 hasRelatedWork W2999627822 @default.
• W3100687825 hasRelatedWork W3000424918 @default.
• W3100687825 hasRelatedWork W3028721771 @default.
• W3100687825 hasRelatedWork W3031812893 @default.
• W3100687825 hasRelatedWork W3084206598 @default.
• W3100687825 hasRelatedWork W3127288106 @default.
• W3100687825 hasRelatedWork W2493531101 @default.
• W3100687825 hasVolume "6" @default.
• W3100687825 isParatext "false" @default.
• W3100687825 isRetracted "false" @default.
• W3100687825 magId "3100687825" @default.
• W3100687825 workType "article" @default.